Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). (Q44813453)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2004

Language	Label	Description	Also known as
English	Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).	scientific article published in April 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Joan Maurel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Joaquín Fra

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Antonio López-Pousa

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Xavier García del Muro

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Antonio Casado

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Javier Martín

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Javier Martínez-Trufero

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Ramón de las Peñas

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

José M Buesa

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Spanish Group for Research on Sarcomas (GEIS)

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

100

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1498-1506

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15042685%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

21 January 2018

Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20115

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44813453&oldid=1566683826"